Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

计划入组 30 人 · 首次发布于 2026 年 4 月 6 日

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects

计划入组 80 人 · 首次发布于 2024 年 7 月 3 日

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

计划入组 104 人 · 首次发布于 2024 年 8 月 27 日

MASH(Repair)

AIM-1

AIM-104

AIM VACCINE

China

AIM Therapeutics, Inc.

Canada

AIM ImmunoTech, Inc.

United States

AI-Based Pathology Tool Validated for Scoring Metabolic Dysfunction-Associated Steatohepatitis

Icosabutate Shows Promising Anti-Fibrotic Results in Phase 2b MASH Trial

AI and Precision Medicine Drive Clinical Trial Innovation as Industry Prepares for 2026 Transformation